BISPECIFIC T-CELL ENGAGER
Talvey is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat relapsed or refractory multiple myeloma in adults who have already tried at least four lines of therapy. These previous therapies must include a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Talvey is also known by its drug name, talquetamab.
Talvey is a bispecific T-cell engager. The drug consists of a genetically engineered protein, or antibody, that targets the GPRC5D protein on B cells — including myeloma cells — and the CD3 protein on T cells. Talvey is believed to work by prompting T cells to kill myeloma cells.
How do I take it?
Talvey is given as a subcutaneous (under the skin) injection. It comes in a single-dose vial. Your doctor will determine the correct dosage schedule for you, and you may need to be monitored in the hospital after your initial doses.
Common side effects of Talvey include cytokine release syndrome (a potentially fatal inflammatory reaction that causes severe neurological symptoms such as hallucinations and tremors), skin problems, rash, fatigue, weight loss, dry mouth, trouble swallowing, headache, musculoskeletal pain, low blood pressure, diarrhea, upper respiratory infections, fever, and changes to the sense of taste.
Rare but serious side effects include oral toxicity, infections, low levels of certain blood cells, skin toxicity and rash, and liver toxicity. Talvey may cause fetal harm for pregnant people.
For more details about this treatment, visit:
Talvey — Janssen Biotech
Talvey — Drugs.com